Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: The Fonda CABG study

Journal of Thrombosis and Thrombolysis

Volumn 32, Issue 3, 2011, Pages 378-385

  Sun, Jack C J ^c   Teoh, Kevin H T ^a   Sheth, Tej ^a   Landry, David ^a   Jung, Hyejung ^b   Warkentin, Theodore E ^a   Yusuf, Salim ^a,b   Lamy, Andre ^a,b   Eikelboom, John W ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c NONE

Author keywords

Anticoagulant; Coronary artery bypass surgery; Fondaparinux; Graft patency

Indexed keywords

FONDAPARINUX; HEPARIN;

ADULT; ARTICLE; BLEEDING; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GRAFT FAILURE; GRAFT OCCLUSION; GRAFT PATENCY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAPHENOUS VEIN GRAFT; STROKE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 82955163019     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0613-6     Document Type: Article

References (33)

1. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R (1994) Effect of coronary artery bypass graft surgery on survival. Lancet 344:563-570
2. Desai ND, Cohen EA, Naylor CD, Fremes SE for the Radial Artery Patency Study investigators (2004) A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med 351:2302-2309 (Pubitemid 39552746)
3. PREVENT IV investigators (2005) Efficacy and safety of edifoligide, an E2F transcription factor decoy for prevention of vein graft failure following coronary artery bypass graft surgery. JAMA 294:2446-2454
4. Serruys PW, Morice MC, Kapptein P, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW for the SYNTAX investigators (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360:961-972
5. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR (1996) Coronary bypass graft fate and patient outcome: angiographic follow-up of 5, 056 grafts related to survival and reoperation in 1, 388 patients during 25 years. J Am Coll Cardiol 26:616-626 (Pubitemid 26288642)
6. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W for the VA Cooperative Study Group #207/297/364 (2004) Long-term patency of saphenous vein and left internal mammary grafts after coronary artery bypass surgery: results from a department of veterans affairs cooperative study. J Am Coll Cardiol 44:2149-2156 (Pubitemid 39576034)
7. Motwani JG, Topol EJ (1998) Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97:916-931 (Pubitemid 28113931)
8. Halabi AR, Alexander JH, Shaw LK, Lorenz TJ, Liao L, Kong DF, Milano CA, Harrington RA, Smith PK (2005) Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. Am J Cardiol 96:1254-1259 (Pubitemid 41505404)
9. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S and the Department of Veterans Affairs Cooperative Study Group (1991) Starting aspirin therapy after operation: effects on early graft patency. Circulation 84:520-526
10. Mangano DT for the Multicenter Study of Perioperative Ischemia Research Group (2002) Aspirin and mortality from coronary bypass surgery. N Engl J Med 347:1309-1317 (Pubitemid 35215321)
11. Simoons ML, Bobbink IWG, Boland J, Gardien M, Klootwijk P, Lensing AWA, Ruzyllo W, Umans VAWM, Vahanian A, Van De Werf F, Zeymer U for the PENTUA Investigators (2004) A dosefinding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 43: 2183-2190
12. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the steering committees of the Pentasaccharide Orthopedic Prophylaxis Studies (2002) Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arc Intern Med 162:1833-1840
13. Cohen AT, Davidson BI, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA for the ARTEMIS investigators (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332:325-329
14. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M on behalf of the PEGASUS investigators (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Brit J Surg 92:1212-1220 (Pubitemid 41475229)
15. Turpie AGG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE on behalf of the APOLLO investigators (2007) Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost 5:1854-1861 (Pubitemid 47288942)
16. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJG, Bassand JP, Wallentin L, Joyner C, Fox KAA for the OASIS-5 investigators (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464-1476
17. Yusuf S, Mehta S, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJG, Bassand JP, Wallentin L, Joyner C, Fox KAA for the OASIS-6 investigators (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute STsegment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519-1530
18. Warkentin TE, Maurer BT, Aster RH (2007) Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 356:2653-2654
19. Rota E, Bazzan M, Fantino G (2008) Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 99:779-781 (Pubitemid 351694236)
20. Kuitunen A, Suojaranata-Ylinen R, Raivio P, Kukkonen S, Lassila R (2007) Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. J Cardiothorac Vasc Anesth 21:18-22 (Pubitemid 46199243)
21. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y (2005) Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparindependent antibodies. Br J Haematol 128:837-841 (Pubitemid 40444878)
22. Liu JC, Lewis BE, Steen LH, Grassman ED, Bakhos M, Blakeman B, Wrona L, Leya F (2002) Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol 89:979-981 (Pubitemid 34310300)
23. Warkentin TE, Greinacher A, Koster A, Lincoff AM (2008) Treatment and prevention of heparin-induced thrombocytopenia: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133:340S-380S (Pubitemid 351892970)
24. Pappalardo F, Scandroglio A, Maj G, Zangrillo A, D'Angelo A (2010) Treatment of heparin-induced thrombocytopenia after cardiac surgery: preliminary experience with fondaparinux. J Thorac Cardiovasc Surg 139:790-792
25. Schussheim AE, Fuster V (1998) Antithrombotic therapy and venous graft disease. Curr Opin Cardiol 13:459-464 (Pubitemid 28502441)
26. Topol EJ, Yadav JS (2000) Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101:570-580 (Pubitemid 30080873)
27. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American college of cardiology/American heart association task force on practice guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). American college of cardiology. Web Site. Available at: http://www.acc.org/clinical/guidelines/cabg/cabg.pdf
28. Kempfer J, Anger K, Rastan A, Krabbes S, Lehmann S, Garbade J, Sauer M, Walther T, Dhein S, Mohr FW (2009) Postoperative development of aspirin resistance following coronary artery bypass. Eur J Clin Invest 39:769-774
29. Sanioglu S, Tetik S, Sokullu O, Deniz H, Aydemir N, Yilmaz M, Arsian IY, Bilgen F (2009) Aspirin resistance after CABG. Thorac Cardiov Surg 57:281-285
30. Zimmermann N, Kurt M, Winter J, Gams E, Wenzel F, Hohlfield T (2008) Detection and duration of aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 135: 947-948 (Pubitemid 351417938)
31. Poston RS, Gu J, Brown JM, Gammie JS, White C, Nie L, Pierson RN, Griffith BP (2006) Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 131:122-130 (Pubitemid 43049792)
32. Yilmaz MB, Balbay Y, Caldir V, Ayaz S, Guray Y, Guray U, Korkmaz S (2005) Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thrombosis Res 115:25-29 (Pubitemid 39572751)
33. Fremes SE, Levinton C, Naylor CD, Chen NE, Christakis GT, Goldman BS (1993) Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. Eur J Cardiothorac Surg 7:169-180